Claris Lifesciences, the Pharma Midcap has posted its Q1 FY17 results on 19thAugust post market hours. The company has reported highly positive top-line and bottom-line numbers on a quarterly basis where net profit has witnessed a triple digit growth.
Claris Lifesciences share price is currently up by almost 3 per cent. In the last month the stock has given a multiple resistance breakout and is likely to remain in the positive trajectory for few more days.
On a quarterly basis the Company’s consolidated revenues for the quarter ended 30th June 2016 have come in at Rs 197.67 crores as against Rs 166.76 crores, an increase of 18.5 per cent. Meanwhile the EBITDA of the Company has risen by 59.3 per cent at Rs 44.19 crores as against Rs 27.74 crores in the last quarter, despite of 96 per cent rise in the cost of raw materials at Rs 34.59 crores.
During the quarter, company’s tax expenses have grown by 82 per cent to Rs 11.58 crores and yet the net profit has risen by 516 per cent to Rs 22 crores from Rs 3.57 crores in Q4 FY16.
The Year on Year (YOY) results show that, Company’s consolidated revenues have dropped by 6.7 per cent from Rs 37.06 crores in the same quarter last year. EBITDA of company too has dropped by 10 per cent from Rs 49.1 crores. However, on a yearly basis, net profit (PAT) of Claris Lifesciences has increased marginally by 8.4 per cent from Rs 20.29 crores in Q1 FY16, despite rise in taxes.
Claris Life deals majorly in specialty injectables; and its USA sales have grown by 106 per cent to Rs 103 crores, which is in line with the company’s long term strategies. However, emerging markets' sales have decreased from Rs 60 crores to Rs 52 crores.
Get the most important support and resistance levels of the share at Claris Lifesciences share price forecast.
No comments:
Post a Comment